New drug duo enters human trials for Tough-to-Treat cancers
NCT ID NCT03454035
Summary
This early-stage trial is testing the safety and best dose of a new two-drug combination (ulixertinib and palbociclib) for people with advanced solid tumors that have stopped responding to standard treatments. It will enroll up to 45 adults, with a specific focus on metastatic pancreatic cancer and certain types of melanoma. The main goal is to find the safest, most effective dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.